Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. - Wikidata - awgldk - TriplyDB

Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.

Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.

http://www.wikidata.org/entity/Q35741383

about

BRCAness: finding the Achilles heel in ovarian cancer How the fanconi anemia pathway guards the genome The combined status of ATM and p53 link tumor development with therapeutic response Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer Therapy Fanconi anemia and the cell cycle: new perspectives on aneuploidy Targeting DNA damage response in cancer therapy Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents Principles of cancer therapy: oncogene and non-oncogene addiction The role of the Fanconi anemia network in the response to DNA replication stress.The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.Mechanisms of a novel anticancer therapeutic strategy involving atmospheric pressure plasma-mediated apoptosis and DNA strand break formation.Human synthetic lethal inference as potential anti-cancer target gene detection Discovery of DNA repair inhibitors by combinatorial library profiling.Hypersensitivity of primordial germ cells to compromised replication-associated DNA repair involves ATM-p53-p21 signaling Mycobacterium tuberculosis Ku can bind to nuclear DNA damage and sensitize mammalian cells to bleomycin sulfate.Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1.BRCAness profile of sporadic ovarian cancer predicts disease recurrence.Characterization of DDRI-18 (3,3'-(1H,3'H-5,5'-bibenzo[d]imidazole-2,2'-diyl)dianiline), a novel small molecule inhibitor modulating the DNA damage response.Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.Replication stress by Py-Im polyamides induces a non-canonical ATR-dependent checkpoint response.ATM signalling and cancer.Loss of ATM kinase activity leads to embryonic lethality in mice Inhibition of DNA glycosylases via small molecule purine analogs Targeting abnormal DNA double strand break repair in cancer The Fanconi anemia pathway and ICL repair: implications for cancer therapy.Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy DNA helicases involved in DNA repair and their roles in cancer Kinase-dead ATM protein causes genomic instability and early embryonic lethality in mice FANCA safeguards interphase and mitosis during hematopoiesis in vivo.Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair Werner syndrome helicase has a critical role in DNA damage responses in the absence of a functional fanconi anemia pathway.CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors DNA damage tolerance: a double-edged sword guarding the genome Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway.

P2860

Q24630872-D0FE8393-B1E5-4B3D-BC38-8C5C4DBA81F5 Q24634556-3188A49E-63C6-416B-99DC-8A6C10B6DAAA Q24652535-76986A8E-1C9B-4567-BE85-EA0BBA868D56 Q26745686-A9D40BE6-09EB-4CC8-9046-553BC35C1DEC Q26783551-42ECDA71-47C4-4813-B637-0E14D6E8EF26 Q26801593-DE3D6229-CF83-4635-BA75-8E82B62AA2CC Q27014905-99929C79-F164-42AE-9127-670441B19D95 Q27023204-9FFEAEB6-0EE4-4CC8-B36C-84C11EFBF45D Q28252640-1EF13328-5B2D-457E-9C7A-BAB2EE6FA9A3 Q28534123-1F0CCDBF-A4D7-4B19-9A4B-A7088BF9A30F Q29616779-1AA70A75-C185-40E2-9546-BF7B8455D952 Q33347783-CD3FA4CF-9EB3-4D88-8235-A4272502691F Q33409459-3A5508DF-06A7-486B-B40D-CB89E2E9E83B Q33465772-76CC47E1-FBD1-49B0-A8A9-269DD2365996 Q33518904-C044A861-6176-4D8C-B1A4-5D7C287DE330 Q33827217-8EC68DF8-CA42-4640-B25B-A4B11426D881 Q33880788-FDCDE105-400A-4AEC-989D-ABEB986F2883 Q33979263-C44B54D5-76E2-4768-9DAE-D4E08DE4561F Q34023194-344A6D15-EB5B-446A-9AB6-0539B1FBEC78 Q34130956-4542EE15-E661-495A-AC85-9C0910CFC92D Q34240365-B3B1729E-E5A9-4765-A21B-5F453E29DA01 Q34248336-8DFB2C13-F833-463E-A429-A1FB5BCB98AB Q34313126-2AD2006D-CFC8-4CD5-AAE2-C30AEBEA8D05 Q34357377-5A7483F5-9B4A-4A53-8B8C-421B01881742 Q34368454-C371404C-C827-408C-B90F-243FB1C960A8 Q34392708-62E71EAE-DBD0-4056-92D3-25C55CF22A21 Q34457557-4E0E6A8D-EEEE-48B2-9248-80622911EEF3 Q35024542-7CE0A264-F69F-458C-94EA-D8CC6121D66B Q35799909-2DE81A25-8725-40DC-8614-8EAF4CFF81F8 Q35828426-8644EEA7-97AB-402C-B65B-8D3D95048767 Q35925499-833DDBE7-3ED9-4548-97BF-397D2B310AC8 Q35961508-7668BD32-ADDE-4F2B-9357-C47D4ACE05CE Q36145724-8F28F0EA-75AA-417B-A6AC-AE57B5A4FE3D Q36338599-2267FD3D-7E6F-44EE-BA22-3D0F364BFBA6 Q36906610-AAE143E0-7A6E-47A6-90B1-3227BD1726B6 Q37041046-B32B4015-468C-4681-8103-6E04607B5328 Q37154365-9859EC4A-7148-4C77-A5E0-4E88947331FE Q37168650-29EB6837-F246-4B0C-95EC-49E69C4D742F Q37187991-1EAA6AF5-804A-421C-81E1-8BD06D700EF9 Q37374618-535A595C-BF3C-4645-B5B1-4FFBD1C7BD20

P2860

Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.

http://www.wikidata.org/entity/Q35741383

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Fanconi anemia pathway-deficie ...... ataxia telangiectasia mutated.

@ast

Fanconi anemia pathway-deficie ...... ataxia telangiectasia mutated.

@en

type

label

Fanconi anemia pathway-deficie ...... ataxia telangiectasia mutated.

@ast

Fanconi anemia pathway-deficie ...... ataxia telangiectasia mutated.

@en

prefLabel

Fanconi anemia pathway-deficie ...... ataxia telangiectasia mutated.

@ast

Fanconi anemia pathway-deficie ...... ataxia telangiectasia mutated.

@en

P1433

Q35741383-C8DE9D28-CABC-4A00-959C-04005AB9EA33

P1476

Q35741383-EC0F9D7B-6DD3-44FC-AE4D-0D2E99B9D1F4

P2093

Q35741383-1FE83A01-7470-47B6-AA49-4ED387EFC9BB

Q35741383-3F8D4E04-37F3-4533-9D5B-FCBB4B85F0F6

Q35741383-44662249-B239-455A-822B-10BF57EB2B19

Q35741383-8A2F1CC9-78AB-4DF0-8AE6-CE8B61B05CEF

Q35741383-97AA1DCB-8656-4E12-B1B1-7D57DE29FF37

Q35741383-BBA4184C-4F12-47D5-92F7-2D1B625ABB56

Q35741383-CE084F0F-75EE-4322-A4DD-E01FDBA086B1

Q35741383-F1910C62-DF8A-42BB-96A2-F3CA740E13C1

P2860

Q35741383-01D19933-6A8E-4B0F-88FC-58ECB58745D1

Q35741383-0983F6A2-975C-4749-A277-1CC8207440FE

Q35741383-0D3A9670-BD14-4FCE-B557-5581E154BC21

Q35741383-18AAE46E-901E-4A7B-AC78-41EB0131D4BB

Q35741383-1A22F62C-AA87-4C3E-BB83-D04100E79B9E

Q35741383-22F9D5FD-1190-4692-967B-75BCD59ABB5A

Q35741383-24B2780A-E9BD-4499-9802-30B581F1AA34

Q35741383-24E2F6B7-A498-442A-AC3A-A35E02F838E9

Q35741383-25DB9F17-8A60-4D94-80E4-06A3A2BFF59E

Q35741383-2AED1BC9-279F-468B-9119-14FABED1FC4D

P304

Q35741383-CAE89A19-91A1-4AFE-B46C-AECEDCA082C1

P31

Q35741383-E4B3A2DD-233A-4AF8-8588-789879BF53A5

P356

Q35741383-728B3F1F-8C31-434E-B5F5-78BD8B2FDF0A

P407

Q35741383-7DDCBE3D-D35B-4E4B-B58C-24A61B1EBEC0

P433

Q35741383-8A82A2BF-1236-4DEA-9D52-6DF510174B92

P478

Q35741383-0AD698C2-133F-4D2A-9042-47E55E61DBB1

P577

Q35741383-3722BED3-6E27-46A9-AAF7-7AEDEE0DA066

P698

Q35741383-A3F0C77F-5253-4379-A602-7C2466382996

P932

Q35741383-605376D0-080B-429C-912D-BBFE9FF70FE7

P356

P1433

Journal of Clinical Investigation

P1476

Fanconi anemia pathway-deficie ...... ataxia telangiectasia mutated.

@en

P2093

Akiko Shimamura

http://www.w3.org/2001/XMLSchema#string

Alan D D'Andrea

http://www.w3.org/2001/XMLSchema#string

Clark C Chen

http://www.w3.org/2001/XMLSchema#string

Elyse M Archila

http://www.w3.org/2001/XMLSchema#string

Lisa A Moreau

http://www.w3.org/2001/XMLSchema#string

Michelle A De la Vega

http://www.w3.org/2001/XMLSchema#string

Patricia Stuckert

http://www.w3.org/2001/XMLSchema#string

Richard D Kennedy

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways

Fanconi anemia proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex

The Fanconi anemia polypeptide FACC is localized to the cytoplasm

Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin

The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations

CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin

In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes

P304

1440-1449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI31245

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2007-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17431503

http://www.w3.org/2001/XMLSchema#string

P932

1847538

http://www.w3.org/2001/XMLSchema#string